Key Drivers
- Stable margins
- Weak liquidity
- Intangible drag
AIAI Summary
CI is no longer just a cheap defensive healthcare stock; the real investment debate now hinges on whether its solid earnings growth and AI-driven cost controls can consistently translate into free cash flow, because the latest quarter's negative cash conversion and thin margins make execution and medical-cost discipline the key proof points for any rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Stable margins
- •Weak liquidity
- •Intangible drag
CI remains a profitable, reasonably valued business with solid interest coverage and cash generation, but weak liquidity, heavy intangibles, and recent negative quarterly cash flow make leverage and book value quality the main risks.
Price Behavior
Key Price Behavior Insights:
- •Higher closes
- •Range rebound
- •Overhead cap
CI has rebounded over the last month with four straight higher closes and support near $273.87-$275.25, but it remains capped below $287-$290 and only turns constructive if it reclaims that range.
Sharp drop from a recent high to the 2026-08-11 low, followed by a rebound on 2026-08-14
Sentiment & News
Key News Insights:
- •Q2 Beat
- •AI Cost Cuts
- •Capital Returns
Cigna's strong Q2 beat, raised outlook, and AI-driven cost-saving push reinforce CI as an attractive value-growth story with steady capital returns.
The news is likely supportive for CI by improving earnings confidence, highlighting cost-management innovation, and reinforcing valuation appeal
Similar Companies in Healthcare
Other companies in the same sector with AI ratings